Cargando…

Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells

BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gbelcová, Helena, Rimpelová, Silvie, Knejzlík, Zdeněk, Šáchová, Jana, Kolář, Michal, Strnad, Hynek, Repiská, Vanda, D’Acunto, Walter Cosimo, Ruml, Tomáš, Vítek, Libor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738693/
https://www.ncbi.nlm.nih.gov/pubmed/29262834
http://dx.doi.org/10.1186/s12944-017-0641-0
_version_ 1783287742250090496
author Gbelcová, Helena
Rimpelová, Silvie
Knejzlík, Zdeněk
Šáchová, Jana
Kolář, Michal
Strnad, Hynek
Repiská, Vanda
D’Acunto, Walter Cosimo
Ruml, Tomáš
Vítek, Libor
author_facet Gbelcová, Helena
Rimpelová, Silvie
Knejzlík, Zdeněk
Šáchová, Jana
Kolář, Michal
Strnad, Hynek
Repiská, Vanda
D’Acunto, Walter Cosimo
Ruml, Tomáš
Vítek, Libor
author_sort Gbelcová, Helena
collection PubMed
description BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in pancreatic cancer. In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins. METHODS: These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). The effect of statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, rosuvastatin, and pitavastatin) and mevalonate intermediates on GFP-K-Ras protein translocation was analyzed using fluorescence microscopy. The changes in gene expression induced in MiaPaCa-2 cells treated with simvastatin, FPP, GGPP, and their combinations with simvastatin were examined by whole genome DNA microarray analysis. RESULTS: All tested statins efficiently inhibited K-Ras protein trafficking from cytoplasm to the cell membrane of the MiaPaCa-2 cells. The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway’s intermediates tested. Expressions of genes involved in metabolic and signaling pathways modulated by simvastatin treatment was normalized by the concurrent addition of FPP or GGPP. K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway. CONCLUSIONS: Our data indicate that the anticancer effects of statins observed in numerous studies to a large extent are mediated through isoprenoid intermediates of the mevalonate pathway, as they influence expression of genes involved in multiple intracellular pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12944-017-0641-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5738693
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57386932017-12-21 Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells Gbelcová, Helena Rimpelová, Silvie Knejzlík, Zdeněk Šáchová, Jana Kolář, Michal Strnad, Hynek Repiská, Vanda D’Acunto, Walter Cosimo Ruml, Tomáš Vítek, Libor Lipids Health Dis Research BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in pancreatic cancer. In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins. METHODS: These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). The effect of statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, rosuvastatin, and pitavastatin) and mevalonate intermediates on GFP-K-Ras protein translocation was analyzed using fluorescence microscopy. The changes in gene expression induced in MiaPaCa-2 cells treated with simvastatin, FPP, GGPP, and their combinations with simvastatin were examined by whole genome DNA microarray analysis. RESULTS: All tested statins efficiently inhibited K-Ras protein trafficking from cytoplasm to the cell membrane of the MiaPaCa-2 cells. The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway’s intermediates tested. Expressions of genes involved in metabolic and signaling pathways modulated by simvastatin treatment was normalized by the concurrent addition of FPP or GGPP. K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway. CONCLUSIONS: Our data indicate that the anticancer effects of statins observed in numerous studies to a large extent are mediated through isoprenoid intermediates of the mevalonate pathway, as they influence expression of genes involved in multiple intracellular pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12944-017-0641-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-20 /pmc/articles/PMC5738693/ /pubmed/29262834 http://dx.doi.org/10.1186/s12944-017-0641-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gbelcová, Helena
Rimpelová, Silvie
Knejzlík, Zdeněk
Šáchová, Jana
Kolář, Michal
Strnad, Hynek
Repiská, Vanda
D’Acunto, Walter Cosimo
Ruml, Tomáš
Vítek, Libor
Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
title Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
title_full Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
title_fullStr Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
title_full_unstemmed Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
title_short Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
title_sort isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738693/
https://www.ncbi.nlm.nih.gov/pubmed/29262834
http://dx.doi.org/10.1186/s12944-017-0641-0
work_keys_str_mv AT gbelcovahelena isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT rimpelovasilvie isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT knejzlikzdenek isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT sachovajana isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT kolarmichal isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT strnadhynek isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT repiskavanda isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT dacuntowaltercosimo isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT rumltomas isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells
AT viteklibor isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells